The clinical spectrum and incidence of anti-MOG-associated acquired demyelinating syndromes in children and adults
The aim of this study was to assess the Dutch nationwide incidence of myelin oligodendrocyte glycoprotein (MOG)-IgG-associated acquired demyelinating syndromes (ADS) and to describe the clinical and serological characteristics of these patients. All serum samples for routine diagnostics from Februar...
Saved in:
| Published in: | Multiple sclerosis Vol. 26; no. 7; p. 1352458519845112 |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
England
01.06.2020
|
| Subjects: | |
| ISSN: | 1477-0970, 1477-0970 |
| Online Access: | Get more information |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | The aim of this study was to assess the Dutch nationwide incidence of myelin oligodendrocyte glycoprotein (MOG)-IgG-associated acquired demyelinating syndromes (ADS) and to describe the clinical and serological characteristics of these patients.
All serum samples for routine diagnostics from February 2014 to December 2017 were sent to the single central reference laboratory for the full-length MOG-IgG cell-based assay (CBA) in the Netherlands. Clinical data from patients known in our National ADS centre were available.
A total of 1414 samples of 1277 patients were received; of these, 92 patients (7%) were MOG-IgG-seropositive. The mean incidence was 0.16/100,000 people, with higher seropositivity in children (0.31/100,000) than in adults (0.13/100,000). In MOG-IgG-positive patients at the National ADS centre (61/92, 66%), the most common presenting phenotype is acute disseminated encephalomyelitis (ADEM, 56%) in children and optic neuritis (ON, 44%) in adults. Relapsing disease occurred in 9/34 (26%) children and 11/27 (41%) adults during median follow-up of 27.5 months. Patients were tested MOG-IgG-positive >200 months after the initial attack, suggesting an extended time to first relapse (TTFR). Longitudinal analysis of MOG-IgG (25/61, 41%) showed that 67% of the monophasic patients remain seropositive and 60% in relapsing patients. Majority of seronegative patients had no relapses (89%).
This nationwide study shows that the overall incidence of MOG-IgG-seropositive disorders is 0.16 per 100,000 people. The distribution over the clinical phenotypes differs between adults and children. Seropositivity can be maintained over years even without clinical activity, while seronegative patients generally had no relapses. |
|---|---|
| AbstractList | The aim of this study was to assess the Dutch nationwide incidence of myelin oligodendrocyte glycoprotein (MOG)-IgG-associated acquired demyelinating syndromes (ADS) and to describe the clinical and serological characteristics of these patients.
All serum samples for routine diagnostics from February 2014 to December 2017 were sent to the single central reference laboratory for the full-length MOG-IgG cell-based assay (CBA) in the Netherlands. Clinical data from patients known in our National ADS centre were available.
A total of 1414 samples of 1277 patients were received; of these, 92 patients (7%) were MOG-IgG-seropositive. The mean incidence was 0.16/100,000 people, with higher seropositivity in children (0.31/100,000) than in adults (0.13/100,000). In MOG-IgG-positive patients at the National ADS centre (61/92, 66%), the most common presenting phenotype is acute disseminated encephalomyelitis (ADEM, 56%) in children and optic neuritis (ON, 44%) in adults. Relapsing disease occurred in 9/34 (26%) children and 11/27 (41%) adults during median follow-up of 27.5 months. Patients were tested MOG-IgG-positive >200 months after the initial attack, suggesting an extended time to first relapse (TTFR). Longitudinal analysis of MOG-IgG (25/61, 41%) showed that 67% of the monophasic patients remain seropositive and 60% in relapsing patients. Majority of seronegative patients had no relapses (89%).
This nationwide study shows that the overall incidence of MOG-IgG-seropositive disorders is 0.16 per 100,000 people. The distribution over the clinical phenotypes differs between adults and children. Seropositivity can be maintained over years even without clinical activity, while seronegative patients generally had no relapses. The aim of this study was to assess the Dutch nationwide incidence of myelin oligodendrocyte glycoprotein (MOG)-IgG-associated acquired demyelinating syndromes (ADS) and to describe the clinical and serological characteristics of these patients.OBJECTIVESThe aim of this study was to assess the Dutch nationwide incidence of myelin oligodendrocyte glycoprotein (MOG)-IgG-associated acquired demyelinating syndromes (ADS) and to describe the clinical and serological characteristics of these patients.All serum samples for routine diagnostics from February 2014 to December 2017 were sent to the single central reference laboratory for the full-length MOG-IgG cell-based assay (CBA) in the Netherlands. Clinical data from patients known in our National ADS centre were available.METHODSAll serum samples for routine diagnostics from February 2014 to December 2017 were sent to the single central reference laboratory for the full-length MOG-IgG cell-based assay (CBA) in the Netherlands. Clinical data from patients known in our National ADS centre were available.A total of 1414 samples of 1277 patients were received; of these, 92 patients (7%) were MOG-IgG-seropositive. The mean incidence was 0.16/100,000 people, with higher seropositivity in children (0.31/100,000) than in adults (0.13/100,000). In MOG-IgG-positive patients at the National ADS centre (61/92, 66%), the most common presenting phenotype is acute disseminated encephalomyelitis (ADEM, 56%) in children and optic neuritis (ON, 44%) in adults. Relapsing disease occurred in 9/34 (26%) children and 11/27 (41%) adults during median follow-up of 27.5 months. Patients were tested MOG-IgG-positive >200 months after the initial attack, suggesting an extended time to first relapse (TTFR). Longitudinal analysis of MOG-IgG (25/61, 41%) showed that 67% of the monophasic patients remain seropositive and 60% in relapsing patients. Majority of seronegative patients had no relapses (89%).RESULTSA total of 1414 samples of 1277 patients were received; of these, 92 patients (7%) were MOG-IgG-seropositive. The mean incidence was 0.16/100,000 people, with higher seropositivity in children (0.31/100,000) than in adults (0.13/100,000). In MOG-IgG-positive patients at the National ADS centre (61/92, 66%), the most common presenting phenotype is acute disseminated encephalomyelitis (ADEM, 56%) in children and optic neuritis (ON, 44%) in adults. Relapsing disease occurred in 9/34 (26%) children and 11/27 (41%) adults during median follow-up of 27.5 months. Patients were tested MOG-IgG-positive >200 months after the initial attack, suggesting an extended time to first relapse (TTFR). Longitudinal analysis of MOG-IgG (25/61, 41%) showed that 67% of the monophasic patients remain seropositive and 60% in relapsing patients. Majority of seronegative patients had no relapses (89%).This nationwide study shows that the overall incidence of MOG-IgG-seropositive disorders is 0.16 per 100,000 people. The distribution over the clinical phenotypes differs between adults and children. Seropositivity can be maintained over years even without clinical activity, while seronegative patients generally had no relapses.CONCLUSIONThis nationwide study shows that the overall incidence of MOG-IgG-seropositive disorders is 0.16 per 100,000 people. The distribution over the clinical phenotypes differs between adults and children. Seropositivity can be maintained over years even without clinical activity, while seronegative patients generally had no relapses. |
| Author | de Mol, C L van Pelt, E D Wokke, Bha Wong, Yym Hintzen, R Q Hamann, D Siepman, Tam Neuteboom, R F |
| Author_xml | – sequence: 1 givenname: C L orcidid: 0000-0002-3733-1706 surname: de Mol fullname: de Mol, C L organization: Department of Neurology, MS Centre ErasMS, Erasmus MC, Rotterdam, The Netherlands – sequence: 2 givenname: Yym surname: Wong fullname: Wong, Yym organization: Department of Neurology, MS Centre ErasMS, Erasmus MC, Rotterdam, The Netherlands – sequence: 3 givenname: E D surname: van Pelt fullname: van Pelt, E D organization: Department of Neurology, MS Centre ErasMS, Erasmus MC, Rotterdam, The Netherlands – sequence: 4 givenname: Bha surname: Wokke fullname: Wokke, Bha organization: Department of Neurology, MS Centre ErasMS, Erasmus MC, Rotterdam, The Netherlands – sequence: 5 givenname: Tam surname: Siepman fullname: Siepman, Tam organization: Department of Neurology, MS Centre ErasMS, Erasmus MC, Rotterdam, The Netherlands – sequence: 6 givenname: R F surname: Neuteboom fullname: Neuteboom, R F organization: Department of Paediatric Neurology, Erasmus MC, Rotterdam, The Netherlands – sequence: 7 givenname: D surname: Hamann fullname: Hamann, D organization: Department of Immunopathology and Blood Coagulation, Sanquin Diagnostic Services, Amsterdam, The Netherlands – sequence: 8 givenname: R Q surname: Hintzen fullname: Hintzen, R Q organization: Department of Neurology, MS Centre ErasMS, Erasmus MC, Rotterdam, The Netherlands |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31094288$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkL1PwzAUxC1URD9gZ0IeWQK248TJiCooSEVdyhyZ5xfqKnFa2xn632NBkZjudO_0k97NycQNDgm55eyBc6UeeV4IWVQFrytZcC4uyIxLpTJWKzb556dkHsKeMaZUXlyRac5ZLUVVzYjf7pBCZ50F3dFwQIh-7Kl2hloH1qADpEObgmiz980q0yEMYHVEQzUcR-uTMdifMDF0tO6LhpMzfugxJAKFne2MR_dD1GbsYrgml63uAt6cdUE-Xp63y9dsvVm9LZ_W2V5KFjOuZSVZjYXgUIJsS8BacgRW5VwyzDE9XKp0w7Jk0BpZMZND0QpE3QpAsSD3v9yDH44jhtj0NgB2nXY4jKERIhcszVaKVL07V8fPHk1z8LbX_tT87SS-AQbebUo |
| ContentType | Journal Article |
| DBID | NPM 7X8 |
| DOI | 10.1177/1352458519845112 |
| DatabaseName | PubMed MEDLINE - Academic |
| DatabaseTitle | PubMed MEDLINE - Academic |
| DatabaseTitleList | PubMed MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1477-0970 |
| ExternalDocumentID | 31094288 |
| Genre | Journal Article |
| GroupedDBID | --- .2E .2J .2N 01A 0R~ 123 18M 1~K 29M 31R 31U 31X 31Z 36B 4.4 53G 54M 5VS 8R4 8R5 AABOD AACMV AACTG AAEWN AAGMC AAJPV AAKGS AAMGE AAPEO AAQXI AARDL AARIX AATAA AATBZ AAUAS ABAFQ ABAWP ABCCA ABCJG ABHFT ABHQH ABJIS ABJNI ABLUO ABNCE ABPNF ABQKF ABQXT ABRHV ABUJY ABVFX ACARO ACDXX ACFEJ ACGFO ACGFS ACGZU ACJER ACJTF ACLFY ACLZU ACOXC ACPRK ACROE ACSIQ ACTQU ACUAV ACUIR ACXKE ACXMB ADBBV ADNON ADRRZ ADVBO ADZYD AECGH AEDTQ AEKYL AENEX AEPTA AERKM AESZF AEUHG AEUIJ AEWDL AEWHI AFKRG AFMOU AFQAA AFUIA AGHKR AGKLV AGNHF AGPXR AGWFA AGWNL AHDMH AHMBA AIOMO AJUZI AJXAJ ALIPV ALKWR ALMA_UNASSIGNED_HOLDINGS ALTZF AMCVQ ANDLU ARTOV AUTPY AYAKG B3H B8R B8Z B94 BBRGL BDDNI BKIIM BKSCU BPACV BSEHC BWJAD BYIEH CS3 DB0 DF0 DO- DU5 DV7 DV9 EBS EJD EMOBN ESX F5P FD6 FHBDP GROUPED_SAGE_PREMIER_JOURNAL_COLLECTION H13 HF~ HZ~ J8X K.F M4V N9A NPM O9- P.B P2P Q1R Q2X Q7L Q7U Q83 ROL S01 SAUOL SCNPE SDB SFC SFK SFT SGO SGR SGV SGZ SHG SNB SPJ SPQ SPV STM ZONMY ZPPRI ZRKOI ZSSAH 7X8 AAPII ABIDT ABJZC ADDLC ADEBD AFKBI AJGYC AJHME AJVBE SASJQ |
| ID | FETCH-LOGICAL-j440t-1a48409e521c6c4f6ce941ec083140e3e511671c6e660cfd480d3c5f2eeaf2ce2 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 179 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000540055900010&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1477-0970 |
| IngestDate | Thu Oct 02 06:33:42 EDT 2025 Wed Feb 19 02:34:08 EST 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 7 |
| Keywords | multiple sclerosis variants Acquired demyelinating syndromes anti-MOG antibodies children incidence adults |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-j440t-1a48409e521c6c4f6ce941ec083140e3e511671c6e660cfd480d3c5f2eeaf2ce2 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0002-3733-1706 |
| OpenAccessLink | https://journals.sagepub.com/doi/pdf/10.1177/1352458519845112 |
| PMID | 31094288 |
| PQID | 2232045162 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2232045162 pubmed_primary_31094288 |
| PublicationCentury | 2000 |
| PublicationDate | 2020-06-01 |
| PublicationDateYYYYMMDD | 2020-06-01 |
| PublicationDate_xml | – month: 06 year: 2020 text: 2020-06-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | Multiple sclerosis |
| PublicationTitleAlternate | Mult Scler |
| PublicationYear | 2020 |
| SSID | ssj0007735 |
| Score | 2.6472054 |
| Snippet | The aim of this study was to assess the Dutch nationwide incidence of myelin oligodendrocyte glycoprotein (MOG)-IgG-associated acquired demyelinating syndromes... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 1352458519845112 |
| Title | The clinical spectrum and incidence of anti-MOG-associated acquired demyelinating syndromes in children and adults |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/31094288 https://www.proquest.com/docview/2232045162 |
| Volume | 26 |
| WOSCitedRecordID | wos000540055900010&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3NS8MwFA_qRLz4_TG_iOA1LEnTpj2JiNODmzuo7DbS5BUm2M118-83L2vZSRC8lNLQUPJek_f5-xFyE8s8B64dy2ReMFVwzgwkEdOg08SJJMsC3dv7s-730-EwG9QBt6ouq2z2xLBRu4nFGHnHH2OInC4SeTv9YsgahdnVmkJjnbQib8qgVuvhCi1c60CwKZTWjGear9KUHeEND4UpsSxFhC75u4EZDpru7n8_cY_s1CYmvVvqxD5Zg_KAbPXqJPohmXnVoE1HJA2tlrPFJzWloxh4DySjdFL4B_Mx6708MlOLEBw1FiuH_Q22oWAru8GyadrgHlR-Btr0h4cZA75HdUTeug-v90-spl5gH0rxORNGoecH_nC3iVVFYiFTAizykikOEcSYv_FjkCTcFk6l3EU2LiSAKaQFeUw2ykkJp4SCEU5Exnva3vOLrcmddl4COhWxk5nJ2-S6Wc2RV23MV5gSJotqtFrPNjlZimQ0XWJwjBDQ1HtO6dkf3j4n2xK95BA7uSCtwv_YcEk27fd8XM2ugs74a3_Q-wFpNcwE |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+clinical+spectrum+and+incidence+of+anti-MOG-associated+acquired+demyelinating+syndromes+in+children+and+adults&rft.jtitle=Multiple+sclerosis&rft.au=de+Mol%2C+C+L&rft.au=Wong%2C+Yym&rft.au=van+Pelt%2C+E+D&rft.au=Wokke%2C+Bha&rft.date=2020-06-01&rft.eissn=1477-0970&rft.spage=1352458519845112&rft_id=info:doi/10.1177%2F1352458519845112&rft_id=info%3Apmid%2F31094288&rft_id=info%3Apmid%2F31094288&rft.externalDocID=31094288 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1477-0970&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1477-0970&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1477-0970&client=summon |